BioAge Labs

What BioAge Labs does

BioAge Labs, Inc. is a clinical-stage biotechnology company developing therapeutics that target the biology of human aging to treat obesity and age-related metabolic diseases. The company is headquartered in Emeryville, California, was co-founded in 2015 by Kristen Fortney, PhD, and Eric Morgen, MD, and has been listed on Nasdaq under the ticker BIOA since its October 2024 initial public offering. BioAge's pipeline is anchored by BGE-102, an oral, brain-penetrant small-molecule NLRP3 inflammasome inhibitor with a novel binding site; BGE-102 demonstrated an 86% median reduction in high-sensitivity C-reactive protein (hsCRP) in Phase 1 trials and entered a 160-adult Phase 2 proof-of-concept trial (QUELL-CV) in June 2026 for cardiovascular risk reduction, with a planned expansion into diabetic macular edema. A second program, an apelin receptor (APJ) agonist, is in preclinical development as an exercise-mimetic to enhance incretin-driven weight loss in obesity, with IND submission anticipated by year-end 2026.

BioAge's core technology is a human-first discovery platform that applies AI/ML-enabled data science to proprietary longitudinal multi-omics data captured over decades from human aging cohorts, supplemented by an in-house translational aging core in naturally aged mice for target validation. The platform has been externally validated through research collaborations with Novartis (a $550M collaboration) and Eli Lilly (Lilly Chorus combination study of azelaprag with Zepbound in obesity), and by a data partnership with Norway's HUNT Biobank. The pipeline also includes two undisclosed discovery-stage cardiometabolic programs.

BioAge is pre-revenue with no marketed products and no disclosed product pricing; future revenue is expected to come from licensing, royalty, and partnership milestone payments rather than direct sales, supported by a cash position of approximately $390M as of Q1 2026 and no long-term debt, providing a stated runway through 2029. The company is led by co-founder/CEO Kristen Fortney, PhD, alongside a leadership team that has contributed to 95+ regulatory approvals, and its board includes representation from major investors Sofinnova Investments, Longitude Capital, and VZVC.

Name

BioAge Labs

Legal name

BioAge Labs, Inc.

Website

https://bioagelabs.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

BioAge Labs is a clinical-stage biotechnology company developing oral, brain-penetrant NLRP3 and APJ agonist therapeutics for obesity and age-related metabolic diseases, supported by an AI/ML-enabled multi-omics discovery platform. Public on Nasdaq as BIOA; pre-revenue.

Ownership category

akta.pro rank

Product category

Metabolic Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro industry

PRIMARYHLAAAIAE

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAAAIAI

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

SECONDARYHLAGAJAO

AI/ML Platforms for Drug Discovery & Experiment Optimization

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)

Keywords

• Aging biology therapeutics
• Metabolic disease drug discovery
• Multi-omics AI platform
• Obesity cardiometabolic therapies
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Emeryville

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. None (Pre-revenue): BioAge Labs is a clinical-stage biopharmaceutical company with no current product revenue. Revenue growth is not expected for years as the drug candidates remain in early clinical development stages. Future potential revenue streams could include licensing/royalty deals, partnership milestone payments, and ultimately product sales if drug candidates are approved.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels6 records

Core offering

BioAge Labs is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics targeting the molecular biology of aging, with a current pipeline focused on an oral NLRP3 inhibitor (BGE-102) for cardiovascular risk and diabetic macular edema, an apelin receptor (APJ) agonist program as an exercise mimetic for obesity, and an oral apelin receptor agonist (azelaprag) being advanced in combination with Eli Lilly's Zepbound. The pipeline is generated and prioritized by BioAge's proprietary human-first multi-omics discovery platform, which uses AI/ML to identify molecular drivers of metabolic aging.

Product overview

BioAge Labs offers a platform-plus-pipeline architecture. The core "Discovery Platform" is a proprietary human-first, multi-omics analysis engine that uses AI/ML to identify molecular drivers of metabolic aging. This platform powers a clinical-stage pipeline of drug candidates: the lead program BGE-102 (an oral, brain-penetrant NLRP3 inhibitor in Phase 1/Phase 2 for cardiovascular risk and diabetic macular edema), the APJ agonist program (oral and parenteral apelin receptor agonists in preclinical/IND-enabling stage for obesity as exercise mimetics to enhance incretin-driven weight loss), and additional earlier discovery-stage programs (Program 1 and Program 2, undisclosed cardiometabolic targets). The platform is externally validated through ongoing research collaborations with Novartis and Eli Lilly.

Differentiator

Problem solved

Functional benefit

Brands

• On Translating Aging: A podcast sponsored by BioAge Labs featuring conversations with researchers, entrepreneurs, and investors moving longevity science from the lab to the clinic.

Products and services

• BGE-102 (oral NLRP3 inhibitor) Oral, potent, highly brain-penetrant small-molecule NLRP3 inflammasome inhibitor with a novel structure and binding site; lead indications are cardiovascular risk reduction and diabetic macular edema. As of mid-2026, BGE-102 is in a Phase 2 proof-of-concept trial (QUELL-CV) following positive Phase 1 data showing up to 86% median reductions in high-sensitivity C-reactive protein.
• APJ Agonist Program Apelin receptor (APJ) agonist program with both oral and long-acting injectable (SQ QW) formulations functioning as an exercise mimetic for obesity. In preclinical models, agonism of APJ has the potential to double weight loss and fully restore body composition when combined with an incretin.
• Azelaprag (oral apelin receptor agonist) Oral apelin receptor agonist being advanced in combination with Eli Lilly's Zepbound (tirzepatide) for obesity and metabolic diseases, conducted through Lilly's Chorus organization.

Quantifiable outcome

• 86% median reduction in high-sensitivity C-reactive protein (hsCRP) at 60mg and 120mg doses of BGE-102 in Phase 1 trial (14-21 days)
• +3 more outcomes

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature4 records

Partnerships

Four partnerships are on record, tiered core, flagship and minor.

• HUNT Biobank (Norway)coreStrategic or Co-development Partner · 7 January 2026BioAge partners with Norway's HUNT Biobank to study human longevity markers and feed its multi-omics discovery platform. The biobank data underpins the company's human-first approach to identifying molecular pathways that drive aging.
• NovartisflagshipStrategic or Co-development Partner · 10 July 2025Novartis has a $550M collaboration with BioAge to advance age-related therapies. BioAge's discovery platform is validated by ongoing research collaborations with Novartis, supporting development of novel therapies targeting aging biology.
• Apple Podcasts and Spotify (Podcast distribution)minorChannel Partner/ Reseller/ Distributor · 10 October 2024BioAge sponsors and distributes the 'On Translating Aging' podcast through Apple Podcasts and Spotify, expanding the reach of its longevity thought leadership content to global audiences.
• Eli LillyflagshipStrategic or Co-development Partner · 13 February 2024BioAge is collaborating with Eli Lilly to advance azelaprag in combination with Lilly's Zepbound (tirzepatide) for obesity and metabolic diseases. The collaboration is conducted through Lilly's Chorus organization, with BioAge's lead program azelaprag entering Phase 2 trials in combination with Zepbound. Lilly's support extends to participation in the Series D financing via Lilly Ventures.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Ventyx Biosciences: Clinical-stage biotech developing oral NLRP3 inhibitors (including VTX3232), directly competing with BioAge's BGE-102 in the same target, similar inflammatory disease indications, and overlapping patient populations.
• Recursion Pharmaceuticals: AI-enabled clinical-stage drug discovery company combining high-throughput biology with machine learning. Highly comparable in business model (platform-plus-pipeline), public-market status, and reliance on computational approaches to identify novel targets.
• Schrödinger, Inc. Computational drug discovery company combining physics-based modeling with machine learning to accelerate small-molecule discovery; comparable in applying computational platforms to drive pipeline asset generation in a publicly traded biotech.
• Structure Therapeutics: Clinical-stage biotech developing oral small-molecule therapies for metabolic diseases including obesity (e.g., oral GLP-1 agonist); directly comparable therapeutic area, modality and obesity / cardiometabolic strategy.
• Viking Therapeutics: Clinical-stage biotech developing therapies for metabolic and endocrine disorders, with a notable obesity candidate (VK2735); comparable stage, target indication (obesity/metabolic), and small-molecule / peptide approach.
• Madrigal Pharmaceuticals: Commercial/specialty biopharma in metabolic liver disease (resmetirom for MASH/NASH); comparable in addressing inflammation-driven metabolic disease with small-molecule therapies and operating in overlapping patient populations.

Emerging players

• Insitro: Machine-learning-driven drug discovery company focused on metabolic disease and neuroscience; overlaps with BioAge in combining proprietary human data with AI/ML to identify drug targets, particularly in metabolic indications.
• Altos Labs: Well-capitalized private biotech focused on cellular rejuvenation and aging biology; directly comparable in mission to translate aging biology into therapeutics and in leveraging proprietary human biology datasets.
• Unity Biotechnology: Clinical-stage biotech developing senolytic and anti-aging therapeutics; overlaps with BioAge in targeting molecular mechanisms of aging to treat age-related metabolic and inflammatory diseases.

Broad incumbents

• Calico Life Sciences (Alphabet): Alphabet-backed R&D organization focused on aging biology and age-related disease; comparable in scientific mission and multi-omics approach to understanding metabolic aging, though with substantially greater resources.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/bioagelabs
• LinkedInlinkedin.com/company/bioage-labs

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds6 records

Investors24 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioAge Labs